{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-026043","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2022-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.704932+00:00","generated_at":"2026-06-24T11:08:21.259620+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Assembly Bio halts vebicorvir, cuts workforce 30%, CFO exits, extends cash to H1 2024","bullets":["Discontinues vebicorvir (VBR) based on interim combo study data showing no benefit in viral parameters.","Advancing next-gen core inhibitors ABI-H3733 (Phase 1b data H2 2022) and ABI-4334 (Phase 1a starts H2 2022).","Workforce reduced ~30% (~70 FTEs); CFO Michael Samar departs Aug 12; COO Jason Okazaki becomes President & COO.","Restructuring costs ~$1.6M; cash runway extended into first half of 2024.","Prioritizes research: HBV/HDV entry inhibitor, IFNAR agonist, two new viral targets (Q3 2022)."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-026043","json":"https://secwatch.observer/filing/0001564590-22-026043.json","markdown":"https://secwatch.observer/filing/0001564590-22-026043.md","text":"https://secwatch.observer/filing/0001564590-22-026043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000156459022026043/0001564590-22-026043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000156459022026043/asmb-8k_20220719.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T11:08:21.259620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c6bc8cef7","claim":"Michael P. Samar departed as Chief Financial Officer at ASSEMBLY BIOSCIENCES, INC..","evidence_excerpt":"Michael P. Samar will depart his roles as the Company's Chief Financial Officer, principal financial officer and principal accounting officer effective August 12, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000156459022026043/0001564590-22-026043-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"9b4e011c68","claim":"Jason A. Okazaki changed role as President and Chief Operating Officer at ASSEMBLY BIOSCIENCES, INC..","evidence_excerpt":"on July 19, 2022, the Board promoted Mr. Okazaki to President and Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000156459022026043/0001564590-22-026043-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}